glp 1 and pancreas GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Cardiovascular, pancreas and brain effects

Bosello S, De Santis M, Lama G, et al

Lysosomal acid lipase as a molecular target of the very low carbohydrate ketogenic diet in morbidly obese patients: the potential effects on liver steatosis and cardiovascular risk factors

In animal models, GIP activation has been shown to reduce inflammation in adipose (fat) tissue and potentially improve how the body stores and mobilizes fat

GLP-1-induced insulin synthesis is initiated by Pdx1

cAMP accumulation assays

This balancing act was attempted by Novo Nordisk, when they developed a triple agonist , compound 16, which in mice was able to reduce body weight by an average of around 30%, fat mass by around 55% and lean mass by around 10% after 27 days [33]